PT3294283T - Regime de dosagem de sacubitril-valsartan para tratar a insuficiência cardíaca - Google Patents

Regime de dosagem de sacubitril-valsartan para tratar a insuficiência cardíaca

Info

Publication number
PT3294283T
PT3294283T PT167223882T PT16722388T PT3294283T PT 3294283 T PT3294283 T PT 3294283T PT 167223882 T PT167223882 T PT 167223882T PT 16722388 T PT16722388 T PT 16722388T PT 3294283 T PT3294283 T PT 3294283T
Authority
PT
Portugal
Prior art keywords
sacubitril
heart failure
dosage regimen
treating heart
valsartan
Prior art date
Application number
PT167223882T
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55967342&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3294283(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT3294283T publication Critical patent/PT3294283T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT167223882T 2015-05-11 2016-05-09 Regime de dosagem de sacubitril-valsartan para tratar a insuficiência cardíaca PT3294283T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562159703P 2015-05-11 2015-05-11

Publications (1)

Publication Number Publication Date
PT3294283T true PT3294283T (pt) 2023-06-07

Family

ID=55967342

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167223882T PT3294283T (pt) 2015-05-11 2016-05-09 Regime de dosagem de sacubitril-valsartan para tratar a insuficiência cardíaca

Country Status (15)

Country Link
US (2) US11058667B2 (pt)
EP (2) EP4212152A1 (pt)
JP (1) JP6576469B2 (pt)
CY (1) CY1126036T1 (pt)
DK (1) DK3294283T3 (pt)
ES (1) ES2945866T3 (pt)
FI (1) FI3294283T3 (pt)
HR (1) HRP20230480T1 (pt)
HU (1) HUE062195T2 (pt)
LT (1) LT3294283T (pt)
PL (1) PL3294283T3 (pt)
PT (1) PT3294283T (pt)
RS (1) RS64242B1 (pt)
SI (1) SI3294283T1 (pt)
WO (1) WO2016181284A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20230480T1 (hr) 2015-05-11 2023-07-21 Novartis Ag Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
WO2020106330A1 (en) * 2018-07-18 2020-05-28 Pillsy, Inc. Smart drug delivery and monitoring device, kit, and method of use for pill compounds
US20210177803A1 (en) 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
WO2021052441A1 (zh) * 2019-09-20 2021-03-25 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物治疗心衰的用途
WO2021230664A1 (ko) * 2020-05-12 2021-11-18 에리슨제약(주) 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0443983T3 (da) 1990-02-19 1996-03-18 Ciba Geigy Ag Acrylforbindelser
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
CN1615134A (zh) 2002-01-17 2005-05-11 诺瓦提斯公司 含有缬沙坦和nep抑制剂的药物组合物
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
ES2536514T3 (es) 2007-11-06 2015-05-26 Novartis Ag Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP)
MA37850A1 (fr) 2012-08-24 2018-07-31 Novartis Ag Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
US20160206597A1 (en) 2013-08-26 2016-07-21 Toni Lynne Bransford New Use
HRP20230480T1 (hr) 2015-05-11 2023-07-21 Novartis Ag Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca

Also Published As

Publication number Publication date
JP2018519266A (ja) 2018-07-19
HUE062195T2 (hu) 2023-10-28
DK3294283T3 (da) 2023-05-30
JP6576469B2 (ja) 2019-09-18
ES2945866T3 (es) 2023-07-10
LT3294283T (lt) 2023-06-12
US20180125820A1 (en) 2018-05-10
US20220133694A1 (en) 2022-05-05
SI3294283T1 (sl) 2023-07-31
EP3294283A1 (en) 2018-03-21
WO2016181284A1 (en) 2016-11-17
RS64242B1 (sr) 2023-06-30
FI3294283T3 (fi) 2023-05-24
EP4212152A1 (en) 2023-07-19
CY1126036T1 (el) 2023-11-15
US11058667B2 (en) 2021-07-13
PL3294283T3 (pl) 2023-07-24
HRP20230480T1 (hr) 2023-07-21
EP3294283B1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
GB201520649D0 (en) Sonodynamic therapy
PT3294283T (pt) Regime de dosagem de sacubitril-valsartan para tratar a insuficiência cardíaca
IL257976A (en) Combined treatment
GB201516442D0 (en) Combination therapy
HK1255110A1 (zh) 組合療法
GB201521217D0 (en) Dosage regimens
IL247084A0 (en) dose fgh–18
GB201514303D0 (en) Bifidobacteria for treating cardiac conditions
GB201418710D0 (en) Dosage regimen
SG10202008024VA (en) Method for Treating Heart Failure
HRP20181756T1 (hr) Režim liječenja sa spojem tiakumicina
IL256576B (en) A new dosing regimen in the thiazomycin compound
GB201521216D0 (en) Dosage regimen
GB201617850D0 (en) Dosage regimen
GB201610502D0 (en) Dosage regimen
GB201518805D0 (en) Therapy
GB201512103D0 (en) Therapeutic treatments
GB201512101D0 (en) Therapeutic treatments
GB201517643D0 (en) Dosage form for melatonin
GB201418708D0 (en) Dosage regimen
GB201506673D0 (en) Combination therapy
GB201500681D0 (en) Combination therapy
GB201400171D0 (en) Dosage regimen
GB201411345D0 (en) Nicotine dosage regimen